Back to top
more

Novo Nordisk (NVO)

(Real Time Quote from BATS)

$134.74 USD

134.74
1,337,535

+2.68 (2.03%)

Updated Sep 19, 2024 01:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?

by Kinjel Shah

PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.

Novo Nordisk (NVO) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Novo Nordisk (NVO) concluded the recent trading session at $132.06, signifying a +0.05% move from its prior day's close.

Sweta Killa headshot

Tap the Weight-Loss Drug Market With These ETFs

by Sweta Killa

Investors seeking to tap the boom in weight-loss drug treatment could consider these ETFs.

Kinjel Shah headshot

Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?

by Kinjel Shah

Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Approves J&J's Tremfya for Ulcerative Colitis & More

by Kinjel Shah

FDA approves J&J's Tremfya for ulcerative colitis. NVO's oral obesity pill, amycretin, shows faster weight loss than weekly injection, Wegovy.

Novo Nordisk (NVO) Outperforms Broader Market: What You Need to Know

by Zacks Equity Research

Novo Nordisk (NVO) reachead $136.66 at the closing of the latest trading day, reflecting a +1.06% change compared to its last close.

Kinjel Shah headshot

NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise

by Kinjel Shah

Stocks of LLY, VKTX and GPCR, which make oral pills for obesity, rose on Wednesday in response to Novo Nordisk's positive data.

Novo Nordisk Stock Rises as Oral Obesity Pill Outshines Wegovy

by Zacks Equity Research

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage study.

Roche Stock Down on Concerns of Side-Effects From Its Obesity Drug

by Zacks Equity Research

RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.

PFE or NVO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PFE vs. NVO: Which Stock Is the Better Value Option?

Should You Invest in the VanEck Pharmaceutical ETF (PPH)?

by Zacks Equity Research

Sector ETF report for PPH

Terns Stock Soars on Positive Data From Phase I Study of Obesity Drug

by Zacks Equity Research

TERN stock soars on positive data from the early-stage study of TERN-601 for obesity, showing statistically significant weight reduction compared to placebo.

Is Novo Nordisk (NVO) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Novo Nordisk (NVO) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research

Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Andrew Rocco headshot

Why you Should Buy the 200-day Dip in ARM, MSTR, VKTX

by Andrew Rocco

The 200-day moving average can provide some of the best long-term entry points. MicroStrategy, Coinbase, and Viking Therapeutics offer high reward-to-risk as they retreat to an important technical level.

Eli Lilly's Weekly Insulin Shot Meets Two Late-Stage Study Goals

by Zacks Equity Research

Data from two late-stage studies show that LLY's once-weekly insulin injections achieved results that are similar to daily insulin shots.

Kinjel Shah headshot

Amgen Stock Rises Almost 20% in 6 Months: Buy, Sell or Hold?

by Kinjel Shah

AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested for now.

Kinjel Shah headshot

AbbVie Stock Up Almost 20% in 3 Months: Buy, Sell or Hold?

by Kinjel Shah

Investors who own ABBV stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

Sundeep Ganoria headshot

Viking Surges 342% in the Past Year: How Should You Play the Stock?

by Sundeep Ganoria

VKTX stock continues to generate phenomenal returns, driven by encouraging development of its obesity and NASH drugs, which are nearing late-stage development.

Kinjel Shah headshot

GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?

by Kinjel Shah

GSK's cheap valuation, reasonable stock price appreciation and bright growth potential indicate that investors should stay invested.

Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Bioventus and Pool have been highlighted as Zacks Bull and Bear of the Day.

Eli Lilly Launches Discounted Versions of Obesity Drug Zepbound

by Zacks Equity Research

LLY's single-dose vials are priced at least 50% lower than the list price of all other GLP-1 medicines for obesity.

Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday

by Zacks Equity Research

VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

Sundeep Ganoria headshot

Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?

by Sundeep Ganoria

Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.